맞춤형 의학 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 페이즈별, 최종 용도별, 서비스별, 유형별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Personalized Medicine Outsourcing Market Size, Share & Trends Analysis Report By Phase (Preclinical, Clinical), By Application (Oncology, Rare Diseases), By Service, By Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

시장 규모와 동향

2024년 1,210억 8,000만 달러로 추정되며 2025년부터 2030년까지 12.47%의 연평균 성장률을 보일 것으로 예상됩니다. 맞춤 의학의 이점에 대한 인식 증가, 희귀 질환, 암, 전염병 등 다양한 질병에 대한 맞춤 의학 적용 증가, 전문 지식의 필요성, 서비스 아웃소싱의 이점 등이 시장 성장을 이끄는 주요 요인 중 일부입니다. 만성 질환, 희귀 질환 및 전염병과 같은 질병의 유병률이 증가함에 따라 이러한 의약품에 대한 수요가 더욱 증가하여 환자 치료 결과가 향상되고 있습니다. 미국 암 협회 보고서인 '암 현황 및 수치 2023'에 따르면 2023년 미국에서 암으로 인해 약 609,820명이 사망하고 같은 해에 1.9명 이상이 진단될 것으로 예상됩니다.

암 치료에서 개인 맞춤형 의학의 적용이 크게 증가했으며, 이는 시장 성장에 기여하는 주요 요인 중 하나입니다. 개인 맞춤 의학 또는 정밀 의학은 특정 암의 조기 발견, 암 위험이 높은 사람 식별, 치료 대안 평가, 치료가 환자의 건강에 미치는 영향 등 종양학에서 여러 적응증에 활용됩니다. 이러한 질병의 부담이 증가함에 따라 개인 맞춤형 의약품에 대한 수요도 증가할 것으로 예상됩니다.

게다가 대부분의 제약 회사가 의약품 개발 및 제조 활동을 이러한 아웃소싱 회사에 아웃소싱하기로 선택함에 따라 지난 몇 년 동안 CRO와 CDMO는 상당한 성장을 목격했습니다. 개발에서 제조에 이르기까지 개인 맞춤형 의약품의 모든 측면에 대한 내부 역량을 구축하고 유지하려면 여러 리소스와 투자가 필요합니다. 따라서 이러한 활동을 아웃소싱하면 기업은 필요에 따라 전문 지식, 인프라 및 리소스를 활용할 수 있어 비용 효율적인 솔루션을 제공할 수 있습니다. 또한 전임상 및 임상 단계에서의 실패와 같은 개인 맞춤형 솔루션 개발과 관련된 복잡성과 위험은 상당한 위험 요소이지만, CRO는 후기 단계의 개발 및 제조의 복잡성을 처리할 수 있으므로 기업은 운영을 간소화하고 효율성을 높일 수 있습니다.

시행착오 처방 감소, 약물 부작용 방지, 예방에서 대응으로 의학적 중요성을 전환하는 등 여러 가지 이점으로 인해 최근 몇 년 동안 맞춤 의약품에 대한 인식이 크게 높아졌습니다. 개인 맞춤 의학은 임상 징후와 증상이 나타나기 전에도 질병의 위험이나 존재를 나타낼 수 있는 분자 마커를 사용하여 질병을 조기에 치료할 수 있어 환자 예후를 개선할 수 있습니다. 마찬가지로 환자가 제공된 치료 및 약물 치료를 준수하지 않으면 지난 몇 년 동안 크게 증가하고 있는 약물 부작용(ADR)과 같은 건강상의 부작용이 발생할 수 있습니다. 따라서 ADR 사례가 증가하면 더 나은 치료 옵션에 대한 사람들의 수요가 증가하여 개인 맞춤형 의약품에 대한 수요를 더욱 촉진할 수 있습니다. 예를 들어(2024년) 1월 미국 국립보건원(NIH)이 발표한 기사에 따르면 2022년 미국에서 약 125만 건의 심각한 부작용이 발생했으며 약 17만 5,000명이 사망한 것으로 기록되었습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 맞춤형 의학 아웃소싱 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 상위 시장 전망
  • 관련 및 보조적인 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 시장 분석 도구
  • Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 맞춤형 의학 아웃소싱 시장 : 페이즈별, 추정 및 동향 분석

• 부문 대시보드
• 세계의 맞춤형 의학 아웃소싱 시장의 위상 변동 분석
• 세계의 맞춤형 의학 아웃소싱 시장 규모와 동향 분석, 페이즈별(2018-2030년)
• 임상
  • 페이즈 I
  • 페이즈 II
  • 페이즈 III
  • 페이즈 IV
• 전임상

제5장 맞춤형 의학 아웃소싱 시장 : 용도별, 추정 및 동향 분석

• 부문 대시보드
• 세계의 맞춤형 의학 아웃소싱 시장의 용도 변동 분석
• 세계의 맞춤형 의학 아웃소싱 시장 규모와 동향 분석, 용도별(2018-2030년)
• 종양학
• 희소질환
• 감염증
• 기타

제6장 맞춤형 의학 아웃소싱 시장 : 서비스별, 추정 및 동향 분석

• 부문 대시보드
• 세계의 맞춤형 의학 아웃소싱 시장의 서비스 변동 분석
• 세계의 맞춤형 의학 아웃소싱 시장 규모와 동향 분석, 서비스별(2018-2030년)
• 계약 제조
• 계약 개발

제7장 맞춤형 의학 아웃소싱 시장 : 유형별, 추정 및 동향 분석

• 부문 대시보드
• 세계의 맞춤형 의학 아웃소싱 시장의 유형 변동 분석
• 세계의 맞춤형 의학 아웃소싱 시장 규모와 동향 분석, 유형별(2018-2030년)
• 억제제
• 단클론항체
• 세포 및 유전자 치료
• 기타

제8장 맞춤형 의학 아웃소싱 시장 : 최종 용도별, 추정 및 동향 분석

• 부문 대시보드
• 세계의 맞춤형 의학 아웃소싱 시장의 최종 용도 변동 분석
• 세계의 맞춤형 의학 아웃소싱 시장 규모와 동향 분석, 최종 용도별(2018-2030년)
• 제약회사
• 생명공학 기업
• 기타

제9장 맞춤형 의학 아웃소싱 시장 : 지역별, 추정 및 동향 분석

• 지역별 시장 점유율 분석(2024년, 2030년)
• 지역별 시장 대시보드
• 시장 규모와 예측 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 기업및 경쟁의 분류
  • 마켓 리더
  • 신흥 진출기업
• 기업시장 포지셔닝 분석(2024년)
• 기업 프로파일
  • Parexel International(MA) Corporation
  • Syneos Health
  • Catalent, Inc
  • ICON
  • Lonza
  • Syngene International Limited
  • HCL Technologies Limited
  • Infosys Limited
  • Fujirebio
  • Aurigene Pharmaceutical Services Ltd.

HBR

영문 목차

영문목차

Market Size & Trends:

The global personalized medicine outsourcing market size was estimated at USD 112.08 billion in 2024 and is projected to grow at a CAGR of 12.47% from 2025 to 2030. The increasing awareness regarding benefits of personalized medicine, increasing application of personalized medicine in various diseases, such as rare diseases, cancer, infectious diseases, and others, the requirement of specialized expertise, and the benefits of outsourcing the services are some of the major factors driving the market growth. The increasing prevalence of diseases such as chronic diseases, rare diseases and infectious diseases is further increasing the demand for these medicines as it offers enhanced patient outcomes. According to the American Cancer Society report, Cancer Facts & Figures 2023, cancer was expected to cause around 609,820 deaths in the U.S. in 2023 and was expected to diagnose over 1.9 people in the same year.

The applications of personalized medicine have significantly increased in cancer care, which is one of the major factors contributing to the market growth. Personalized medicine or precision medicine is utilized for several indications in oncology such as early detection of certain cancers, identifying people with higher cancer risk, evaluation of treatment alternatives, and effect of treatment on patient's health. As the burden of these diseases increase, the demand for personalized medicine is also anticipated to witness growth.

Furthermore, CROs and CDMOs have witnessed significant growth during the past few years as most of the pharmaceutical companies are opting to outsource their drug development and manufacturing activities to these outsourcing companies. Building and maintaining internal capabilities for all aspects of personalized medicine, from development to manufacturing, requires several resources and investments. Therefore, outsourcing these activities can allow companies to access specialized expertise, infrastructure, and resources according to their needs, thereby offering a cost-effective solution. Moreover, the complexity and risk associated with the development of personalized solutions, such as failures in the preclinical and clinical phases, offer a significant risk factor, while CROs can handle the complexities of later-stage development and manufacturing, allowing companies to streamline their operations and enhance their efficiency.

The awareness about personalized medicine has significantly increased in recent years owing to its several benefits, such as reducing trial and error prescribing, helping in avoiding adverse drug reactions, and shifting the medical importance from prevention to reaction. Personalized medicine offers the ability to use molecular markers that can indicate disease risk or presence even before clinical signs and symptoms appear, allowing for early treatments of diseases and thereby improving patient outcomes. Similarly, the patient's non-compliance with offered treatment and medication can lead to adverse health effects such as Adverse Drug Reactions (ADR), which have been on a significant rise in past years. Thus, increasing cases of ADRs would boost the demand for better treatment options among people further driving the demand for personalized medicine. For instance, according to an article published by the National Institute of Health (NIH) in January 2024, there were around 1.25 million serious adverse effects and approximately 175,000 deaths were recorded in the U.S. in 2022.

Global Personalized Medicine Outsourcing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global personalized medicine outsourcing market report based on phase, application, service, type, end use, and region.

• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Clinical
• Phase I
• Phase II
• Phase III
• Phase IV
• Preclinical
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Oncology
• Rare Diseases
• Infectious Diseases
• Others
• Service Outlook (Revenue, USD Million, 2018 - 2030)
• Contract Manufacturing
• Contact Development
• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Inhibitor Drugs
• Monoclonal Antibodies
• Cell & Gene Therapy
• Other Therapeutic Products
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceutical Companies
• Biotechnology Companies
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information analysis
  • 1.3.2. Data validation & publishing
  • 1.3.3. Information Procurement
  • 1.3.4. Primary Research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Research Models
  • 1.6.1. Commodity Flow Analysis
  • 1.6.2. Bottom-up Approach
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Personalized Medicine Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of chronic and rare diseases
    • 3.2.1.2. Increasing awareness about the benefits of personalized medicine
    • 3.2.1.3. Increasing application of personalized medicine in various diseases
    • 3.2.1.4. Requirement of specialized expertise for personalized medicine development and manufacturing
  • 3.2.2. Market restraints analysis
    • 3.2.2.1. Data privacy concerns
    • 3.2.2.2. Compliance issues with outsourcing
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's five forces analysis
  • 3.3.2. PESTEL analysis
  • 3.3.3. COVID-19 impact analysis

Chapter 4. Personalized Medicine Outsourcing Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Personalized Medicine Outsourcing Market Product Movement Analysis
• 4.3. Global Personalized Medicine Outsourcing Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Clinical
  • 4.4.1. Clinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Phase I
    • 4.4.2.1. Phase I Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Phase II
    • 4.4.3.1. Phase II Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Phase III
    • 4.4.4.1. Phase III Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. Phase IV
    • 4.4.5.1. Phase IV Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 4.5. Preclinical
  • 4.5.1. Preclinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 5. Personalized Medicine Outsourcing Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Personalized Medicine Outsourcing Market Application Movement Analysis
• 5.3. Global Personalized Medicine Outsourcing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Oncology
  • 5.4.1. Oncology Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 5.5. Rare Diseases
  • 5.5.1. Rare Diseases Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 5.6. Infectious Diseases
  • 5.6.1. Infectious Diseases Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 6. Personalized Medicine Outsourcing Market: Service Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Personalized Medicine Outsourcing Market Service Movement Analysis
• 6.3. Global Personalized Medicine Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
• 6.4. Contract Manufacturing
  • 6.4.1. Contract Manufacturing Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 6.5. Contact Development
  • 6.5.1. Contact Development Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 7. Personalized Medicine Outsourcing Market: Type Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Personalized Medicine Outsourcing Market Type Movement Analysis
• 7.3. Global Personalized Medicine Outsourcing Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 7.4. Inhibitor Drugs
  • 7.4.1. Inhibitor Drugs Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 7.5. Monoclonal Antibodies
  • 7.5.1. Monoclonal Antibodies Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 7.6. Cell & Gene Therapy
  • 7.6.1. Cell & Gene Therapy Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 8. Personalized Medicine Outsourcing Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Personalized Medicine Outsourcing Market End Use Movement Analysis
• 8.3. Global Personalized Medicine Outsourcing Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 8.4. Pharmaceutical Companies
  • 8.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 8.5. Biotechnology Companies
  • 8.5.1. Biotechnology Companies Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 8.6. Others
  • 8.6.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 9. Personalized Medicine Outsourcing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 9.4. North America
  • 9.4.1. North America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.4.2. U.S.
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Competitive scenario
    • 9.4.2.3. Regulatory framework
    • 9.4.2.4. U.S. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Competitive scenario
    • 9.4.3.3. Regulatory framework
    • 9.4.3.4. Canada Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Competitive scenario
    • 9.4.4.3. Regulatory framework
    • 9.4.4.4. Mexico Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Competitive scenario
    • 9.5.2.3. Regulatory framework
    • 9.5.2.4. UK Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Competitive scenario
    • 9.5.3.3. Regulatory framework
    • 9.5.3.4. Germany Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Competitive scenario
    • 9.5.4.3. Regulatory framework
    • 9.5.4.4. France Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Competitive scenario
    • 9.5.5.3. Regulatory framework
    • 9.5.5.4. Italy Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Competitive scenario
    • 9.5.6.3. Regulatory framework
    • 9.5.6.4. Spain Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.7. Norway
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Competitive scenario
    • 9.5.7.3. Regulatory framework
    • 9.5.7.4. Norway Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.8. Sweden
    • 9.5.8.1. Key country dynamics
    • 9.5.8.2. Competitive scenario
    • 9.5.8.3. Regulatory framework
    • 9.5.8.4. Sweden Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.5.9. Denmark
    • 9.5.9.1. Key country dynamics
    • 9.5.9.2. Competitive scenario
    • 9.5.9.3. Regulatory framework
    • 9.5.9.4. Denmark Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.6.2. Japan
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Competitive scenario
    • 9.6.2.3. Regulatory framework
    • 9.6.2.4. Japan Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.6.3. China
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Competitive scenario
    • 9.6.3.3. Regulatory framework
    • 9.6.3.4. China Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Competitive scenario
    • 9.6.4.3. Regulatory framework
    • 9.6.4.4. India Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.6.5. Australia
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Competitive scenario
    • 9.6.5.3. Regulatory framework
    • 9.6.5.4. Australia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.6.6. South Korea
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Competitive scenario
    • 9.6.6.3. Regulatory framework
    • 9.6.6.4. South Korea Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Competitive scenario
    • 9.6.7.3. Regulatory framework
    • 9.6.7.4. Thailand Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Competitive scenario
    • 9.7.2.3. Regulatory framework
    • 9.7.2.4. Brazil Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Competitive scenario
    • 9.7.3.3. Regulatory framework
    • 9.7.3.4. Argentina Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 9.8. MEA
  • 9.8.1. MEA Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Competitive scenario
    • 9.8.2.3. Regulatory framework
    • 9.8.2.4. South Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Competitive scenario
    • 9.8.3.3. Regulatory framework
    • 9.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key country dynamics
    • 9.8.4.2. Competitive scenario
    • 9.8.4.3. Regulatory framework
    • 9.8.4.4. UAE Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key country dynamics
    • 9.8.5.2. Competitive scenario
    • 9.8.5.3. Regulatory framework
    • 9.8.5.4. Kuwait Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
  • 10.1.1. Market Leaders
  • 10.1.2. Emerging Players
• 10.2. Company Market Position Analysis, 2024
• 10.3. Company Profiles
  • 10.3.1. Parexel International (MA) Corporation
    • 10.3.1.1. Company overview
    • 10.3.1.2. Financial performance
    • 10.3.1.3. Service benchmarking
    • 10.3.1.4. Strategic initiatives
  • 10.3.2. Syneos Health
    • 10.3.2.1. Company overview
    • 10.3.2.2. Financial performance
    • 10.3.2.3. Service benchmarking
    • 10.3.2.4. Strategic initiatives
  • 10.3.3. Catalent, Inc
    • 10.3.3.1. Company overview
    • 10.3.3.2. Financial performance
    • 10.3.3.3. Service benchmarking
    • 10.3.3.4. Strategic initiatives
  • 10.3.4. ICON
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Service benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Lonza
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Service benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Syngene International Limited
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Service benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. HCL Technologies Limited
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Service benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Infosys Limited
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Service benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Fujirebio
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Service benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Aurigene Pharmaceutical Services Ltd.
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Service benchmarking
    • 10.3.10.4. Strategic initiatives

관련자료